Biohaven Ltd (BHVN)

Feb 11, 2025, 5:47 PM EST - 11 days ago

Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck

Feb 11, 2025, 7:30 AM EST - 11 days ago

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

Jan 13, 2025, 11:15 AM EST - 5 weeks ago

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy

Jan 7, 2025, 5:54 PM EST - 6 weeks ago

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 2:23 PM EST - 2 months ago

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval

Dec 16, 2024, 7:30 AM EST - 2 months ago

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates

Dec 6, 2024, 7:30 AM EST - 2 months ago

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

Nov 29, 2024, 5:30 AM EST - 3 months ago

Biohaven's Revenue Path: SCA And Obesity Therapies

Nov 25, 2024, 8:32 AM EST - 3 months ago

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session

SAVA

Nov 25, 2024, 7:45 AM EST - 3 months ago

Biohaven's spinal muscular atrophy drug fails to meet main goal in study

Nov 25, 2024, 7:30 AM EST - 3 months ago

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

Nov 12, 2024, 4:05 PM EST - 3 months ago

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

Oct 2, 2024, 4:05 PM EDT - 5 months ago

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 1, 2024, 6:00 AM EDT - 5 months ago

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

Sep 30, 2024, 4:05 PM EDT - 5 months ago

Biohaven Announces Proposed Public Offering of Common Shares

Sep 30, 2024, 7:30 AM EDT - 5 months ago

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Sep 23, 2024, 5:02 PM EDT - 5 months ago

Overlooked Stock: BHVN

Sep 23, 2024, 2:55 PM EDT - 5 months ago

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Sep 23, 2024, 2:40 PM EDT - 5 months ago

Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug

Sep 23, 2024, 11:22 AM EDT - 5 months ago

Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise

Sep 23, 2024, 9:18 AM EDT - 5 months ago

Biohaven's stock surges as treatment slows progress of neurological disorder

Sep 23, 2024, 8:03 AM EDT - 5 months ago

Biohaven's genetic disease drug meets main trial goal

Sep 23, 2024, 7:30 AM EDT - 5 months ago

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

Sep 20, 2024, 7:09 PM EDT - 5 months ago

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

Aug 8, 2024, 4:05 PM EDT - 7 months ago

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments

Jul 26, 2024, 11:48 AM EDT - 7 months ago

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

May 29, 2024, 7:30 AM EDT - 9 months ago

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

May 29, 2024, 7:15 AM EDT - 9 months ago

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

REGN

May 18, 2024, 3:10 AM EDT - 10 months ago

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

May 9, 2024, 4:05 PM EDT - 10 months ago

Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments

Apr 18, 2024, 6:00 AM EDT - 11 months ago

Biohaven Announces Pricing of $230 Million Public Offering of Common Shares

Apr 13, 2024, 9:00 AM EDT - 11 months ago

Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates

Mar 25, 2024, 6:19 PM EDT - 11 months ago

How Biohaven's experimental obesity drug could prevent muscle loss

Feb 29, 2024, 4:05 PM EST - 1 year ago

Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments

Feb 28, 2024, 12:48 PM EST - 1 year ago

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Jan 8, 2024, 7:30 AM EST - 1 year ago

Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncol

Jan 2, 2024, 7:00 AM EST - 1 year ago

Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 4:30 PM EST - 1 year ago

Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting

Nov 14, 2023, 4:05 PM EST - 1 year ago

Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Oct 2, 2023, 11:56 PM EDT - 1 year ago

Biohaven Announces Pricing of $225 Million Public Offering of Common Shares

Oct 2, 2023, 4:36 PM EDT - 1 year ago

BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

Sep 14, 2023, 7:00 AM EDT - 1 year ago

Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy

Sep 5, 2023, 7:00 AM EDT - 1 year ago

Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies

Jul 31, 2023, 9:31 AM EDT - 1 year ago

Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy

Jul 31, 2023, 6:59 AM EDT - 1 year ago

Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments

Jul 27, 2023, 7:00 AM EDT - 1 year ago

Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates

Jun 14, 2023, 1:09 PM EDT - 1 year ago

Biohaven: A Promising Investment In Innovative Neurological Therapies

May 31, 2023, 7:00 AM EDT - 1 year ago

Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day